[General Information]
[Abstracts]
[How to Contact Us]
 

EFFECT OF HYDRAZINE SULPHATE ON WHOLE-BODY PROTEIN BREAKDOWN MEASURED BY C-LYSINE METABOLISM IN LUNG CANCER PATIENTS

[Lancet 2:241-244, 1987]

JOHN A. TAYEK, DAVID HEBER, ROWAN T. CHLEBOWSKI

Department of Medicine, UCLA School of Medicine, Divisions of Endocrinology, Metabolism and Nutrition, and Medical Oncology, Harbor-UCLA Medical Center, Torrance, California, USA; and Division of Clinical Nutrition, Center of Health Sciences, Los Angeles, California

Summary

In a prospective double-blind trial twelve malnourished patients with lung cancer were randomised to receive either placebo or hydrazine sulphate (60 mg three times daily) for 30 days. Fasting lysine flux was determined by a primed 4-hour continuous infusion of C-lysine before and after one month of hydrazine treatment. Baseline plasma lysine flux was 2580 (SD 580) mmol/h for the placebo group and 2510 (440) mmol/h for the hydrazine group. After one month the placebo group showed a slight rise to 2920 (450) mmol/h (p=0.08) and the hydrazine group showed a significant fall to 1840 (750) mmol/h (p<0.05); serum albumin fell in the placebo group and was unchanged in the hydrazine group. Administration of hydrazine sulphate to reduce aminoacid flux may favourably influence the metabolic abnormalities in cancer cachexia.


This page is designed and hosted by Next Generation Computer Systems, and is the property of the Syracuse Cancer Research Institute. 1996, Syracuse Cancer Research Institute. All rights reserved.
Last modified on 04 June 1998 by
webteam@ngen.com.